Scarica l'app Stockscreener
35.38
0.86%
0.30
Precedente Chiudi:
$35.08
Aprire:
$35.38
Volume 24 ore:
384.20K
Relative Volume:
0.53
Capitalizzazione di mercato:
$2.06B
Reddito:
$32.87M
Utile/perdita netta:
$674.31M
Rapporto P/E:
3.1144
EPS:
11.36
Flusso di cassa netto:
$-330.11M
1 W Prestazione:
-2.29%
1M Prestazione:
-9.40%
6M Prestazione:
+7.83%
1 anno Prestazione:
-20.92%
Intervallo 1D:
$35.11
$36.16
Intervallo di 1 settimana:
$34.71
$37.86
Portata 52W:
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Nome
Agios Pharmaceuticals Inc
Settore
Industria
Telefono
617-649-8600
Indirizzo
88 SIDNEY STREET, CAMBRIDGE, MA
Confronta AGIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
35.38 | 2.04B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-24 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-27 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Iniziato | Piper Sandler | Overweight |
| 2022-11-17 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-27 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-02-15 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Iniziato | Leerink Partners | Mkt Perform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-04-11 | Reiterato | Credit Suisse | Outperform |
| 2018-02-15 | Reiterato | Needham | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-08-10 | Reiterato | Needham | Buy |
| 2017-08-08 | Reiterato | SunTrust | Buy |
| 2017-08-02 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Downgrade | Janney | Buy → Neutral |
| 2017-01-17 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Iniziato | Needham | Buy |
| 2016-06-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Reiterato | SunTrust | Buy |
Mostra tutto
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
Can Agios Pharmaceuticals Inc. Regain Lost Ground This QuarterMarket Entry and Exit Point Tips From Traders - 선데이타임즈
Agios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last? - MSN
Agios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For Shareholders - Yahoo Finance
TD Cowen reiterates Buy rating on Agios Pharma stock amid safety concerns - Investing.com Canada
Agios (AGIO) Q2 Revenue Jumps 45% - AOL.com
Agios: Patients’ deaths don’t alter Pyrukynd’s benefit-risk profile - BioWorld MedTech
Report of Patient Deaths Sends Agios Shares Seesawing - BioSpace
Agios falls as Leerink cites deaths linked to lead asset Pyrukynd - MSN
SFDA approves Agios Pharma’s Pyrukynd for thalassemia - Yahoo Finance
Agios Pharmaceuticals addresses analyst report on PYRUKYND safety data By Investing.com - Investing.com Nigeria
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia - The Manila Times
Breakthrough: Saudi Arabia Approves First-Ever Oral Treatment for All Adult Thalassemia Patients - Stock Titan
Chartists See Breakout Potential in Agios Pharmaceuticals Inc.Fast Exit and Entry Strategy Guide Offered - beatles.ru
Agios evaluating fourth Pyrukynd case after analyst report - TipRanks
Agios Pharma’s PYRUKYND Approved by Saudi Authority - TipRanks
Agios Pharmaceuticals addresses analyst report on PYRUKYND safety data - Investing.com
Agios Pharmaceuticals: Navigating Pyrukynd's Thalassemia PDUFA and Sickle Cell Pipeline Risks Amid Recent Valuation Pressure - AInvest
Agios stock falls on Pyrukynd-related deaths (AGIO:NASDAQ) - Seeking Alpha
Agios shares drop after report notes deaths of Pyrukynd patients By Investing.com - Investing.com Canada
What makes Agios Pharmaceuticals Inc. stock price move sharplyMarket-leading profit generation - Jammu Links News
How strong is Agios Pharmaceuticals Inc. company’s balance sheetBuild a winning investment portfolio - Jammu Links News
Agios Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding risk-reward balance - Jammu Links News
What analysts say about Agios Pharmaceuticals Inc. stockMaximize gains with proven stock analysis - Jammu Links News
What is the risk reward ratio of investing in Agios Pharmaceuticals Inc. stockConsistent high-performance stocks - Jammu Links News
What are Agios Pharmaceuticals Inc. company’s key revenue driversCapitalize on fast-moving stock opportunities - Jammu Links News
What are the latest earnings results for Agios Pharmaceuticals Inc.Superior investment outcomes - Jammu Links News
When is Agios Pharmaceuticals Inc. stock expected to show significant growthAchieve rapid portfolio appreciation today - Jammu Links News
What is Agios Pharmaceuticals Inc. company’s growth strategyBuild wealth steadily with proven strategies - Jammu Links News
What are the technical indicators suggesting about Agios Pharmaceuticals Inc.Capitalize on market momentum for maximum gains - Jammu Links News
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates - MSN
Agios Pharmaceuticals Q2 2025: Unraveling Key Contradictions in Safety, Spending, and Pediatric Strategy - AInvest
Agios expects modest full-year 2025 revenue growth with PYRUKYND thalassemia launch pending FDA approval - MSN
Why is Agios Pharmaceuticals Inc. stock attracting strong analyst attentionDaily Trading Forecasts From AI Tools - Jammu Links News
A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $50 to $65 - 富途牛牛
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2025 Earnings Call Transcript - Insider Monkey
Agios 2025 Q2 Earnings Misses Targets as Net Income Declines 16.5% - AInvest
Agios Pharmaceuticals Inc (AGIO) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada
Agios Pharmaceuticals Inc (AGIO) Q2 2025 Earnings Call Highlight - GuruFocus
Agios Pharmaceuticals: Q2 Earnings Snapshot - Greenwich Time
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi - GuruFocus
Agios Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Agios Pharmaceuticals: Navigating Earnings Volatility for Long-Term Growth in Rare Disease Therapeutics - AInvest
Earnings call transcript: Agios Pharm Q2 2025 earnings miss EPS, stock dips - Investing.com Canada
AGIOS PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Agios Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
How many analysts rate Agios Pharmaceuticals Inc. as a “Buy”Top Growth Target Finder To Watch Now - jammulinksnews.com
Agios Pharmaceuticals Q2 2025 Revenue Beats Estimates: A Glimmer of Growth in a Continuously Loss-Making Biotech - AInvest
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Agios Pharmaceuticals Reports $12.5 Million in Q2 2025 PYRUKYND® Revenues and Highlights Key Regulatory Developments - Quiver Quantitative
Agios Pharmaceuticals: Earnings Beat and Pipeline Offer Glimmers of Hope in Biotech's Volatile Landscape - AInvest
Intrahepatic Cholangiocarcinoma Market: Epidemiology, - openPR.com
Agios Pharmaceuticals Inc Azioni (AGIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):